Deal Details
Harpoon Therapeutics Completes $115 Million Follow-On Offering
Summary
Harpoon Therapeutics, Inc. (“Harpoon Therapeutics”) (NASDAQ-GS:HARP) recently completed an underwritten public offering of 6,764,704 shares of its common stock at a public price of $17.00 per share. The offering included the exercise in full by the underwriters of their option to purchase an additional 882,352 shares of common stock at the public offering price. The total gross proceeds to Harpoon Therapeutics from the offering are approximately $115.0 million.
Baird served as a co-lead manager on this offering.
About
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon Therapeutics is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon Therapeutics, Inc. is headquartered in South San Francisco, California.CONTACT US TO LEARN MORE
- Date
- January 2021
- Company
- Harpoon Therapeutics, Inc.
- Transaction
- Equity Capital Markets
- Sectors
- Healthcare
- Verticals
-
Biotechnology & Pharmaceuticals
- Target Geography
- North America
Share
